{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T12:46:15Z","timestamp":1768740375167,"version":"3.49.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T00:00:00Z","timestamp":1542326400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Health Research Council","award":["11\/203"],"award-info":[{"award-number":["11\/203"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13075-018-1755-0","type":"journal-article","created":{"date-parts":[[2018,11,16]],"date-time":"2018-11-16T08:13:58Z","timestamp":1542356038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose"],"prefix":"10.1186","volume":"20","author":[{"given":"Lisa K.","family":"Stamp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter T.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murray L.","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Horne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Frampton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Drake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"key":"1755_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"K Hande","year":"1984","unstructured":"Hande K, Noone R, Stone W. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47\u201356.","journal-title":"Am J Med"},{"issue":"8","key":"1755_CR2","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1002\/art.34488","volume":"64","author":"L Stamp","year":"2012","unstructured":"Stamp L, Taylor W, Jones P, Dockerty J, Drake J, Frampton C, Dalbeth N. Starting dose, but not maximum maintenance dose, is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64(8):2529\u201336.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1755_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, Coyfish M, Guillo S, Janesen T, Janssens H, et al. 2016 Updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1755_CR4","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald J, Khanna P, Sangmee B, Singh M, Neogi T, Pillinger M, Merill J, Lee S, Prakash S, et al. 2012 American College of Rheumatology guidelines for the management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricaemia. Arthritis Care Res. 2012;64(10):1431\u201346.","journal-title":"Arthritis Care Res"},{"issue":"8","key":"1755_CR5","first-page":"1646","volume":"33","author":"N Dalbeth","year":"2006","unstructured":"Dalbeth N, Kumar S, Stamp LK, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricaemia in patients with gout. J Rheumatol. 2006;33(8):1646\u201350.","journal-title":"J Rheumatol"},{"key":"1755_CR6","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","volume":"76","author":"L Stamp","year":"2017","unstructured":"Stamp L, Chapman P, Barclay M, Horne A, Frampton C, Tan P, Drake J, Dalbeth N. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017;76:1522\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1755_CR7","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1136\/annrheumdis-2017-211873","volume":"76","author":"L Stamp","year":"2017","unstructured":"Stamp L, Chapman P, Barclay M, Horne A, Frampton C, Tan P, Drake J, Dalbeth N. Allopurinol dose escalation to achieve serum urate below 6mg\/dl: an open label extension study. Ann Rheum Dis. 2017;76:2065\u201370.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1755_CR8","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","volume":"46","author":"R Day","year":"2007","unstructured":"Day R, Graham G, Hicks M, McLachlan A, Stocker S, Williams K. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet. 2007;46(8):623\u201344.","journal-title":"Clin Pharmacokinet"},{"issue":"13","key":"1755_CR9","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"William B. White","year":"2018","unstructured":"White W, Saag K, Becker M, Borer J, Gorelick P, Whelton A, Hunt B, Castillo M, Gunawardhana L. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1710895\n                    \n                  .","journal-title":"New England Journal of Medicine"},{"key":"1755_CR10","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12872-018-0757-9","volume":"18","author":"M Bredemeier","year":"2018","unstructured":"Bredemeier M, Lopes L, Eisenreich M, Hickmann S, Bongiorno G, d'Avila R. Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2018;18:24.","journal-title":"BMC Cardiovasc Disord"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1755-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1755-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1755-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T19:28:14Z","timestamp":1573846094000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1755-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,16]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1755"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1755-0","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,16]]},"assertion":[{"value":"19 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was obtained from the Multi-Regional Ethics Committee, New Zealand. Written informed consent was obtained from each participant.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Prof. Stamp reports grants from the Health Research Council of New Zealand during the conduct of the study; grants from Ardea Biosciences, grants from the Health Research Council of New Zealand, outside the submitted work; Dr Chapman has nothing to disclose: Prof. Barclay has nothing to disclose; Dr Horne reports grants from the Health Research Council of New Zealand during the conduct of the study; Prof. Frampton has nothing to disclose; Mrs Drake has nothing to disclose; Mr Tan has nothing to disclose; Prof. Dalbeth reports grants from the Health Research Council of New Zealand during the conduct of the study; grants from the Health Research Council of New Zealand, grants and personal fees from AstraZeneca, grants and personal fees from Ardea Biosciences, grants from Amgen, personal fees from Takeda, personal fees from Horizon and personal fees from Kowa, outside the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"255"}}